![]() |
市場調査レポート
商品コード
1380454
心臓ポンプ装置の世界市場:2023~2030年Global Heart Pump Device Market 2023-2030 |
||||||
カスタマイズ可能
|
心臓ポンプ装置の世界市場:2023~2030年 |
出版日: 2023年10月01日
発行: Orion Market Research
ページ情報: 英文 205 Pages
納期: 2~3営業日
|
世界の心臓ポンプ装置市場は、予測期間(2023~2030年)にCAGR 21.4%で成長すると予測されています。心血管疾患(CVD)に罹患する個人の増加、心不全の発生率の上昇などの極めて重要な要因が市場の成長を促進しています。世界保健機関(WHO)によると、心血管疾患(CVD)は世界の死因のトップであり、毎年推定1,790万人の命を奪っています。さらに、心臓ポンプ製品の研究開発への投資の増加は、これらの装置の受け入れと使用の増加を促進することにより、市場の成長を促進すると予測されています。2022年10月、全人工心臓を開発する前臨床医療機器企業であるBiVACOR(R)は、オーストラリア政府からMRFF(Medical Research Future Fund)とTTRA(Targeted Translation Research Accelerator)プログラムを通じて75万米ドルの助成金を受けた。
製品別では、補助人工心臓が世界の心臓ポンプ市場で大きなシェアを占めると予想されています。このセグメントの成長は、一時的な心不全の発生率の上昇、ドナー心臓が利用可能になるのを待っている間のLVADの一時的な使用、年齢やその他の要因のために心臓移植を受けることができないLVADの使用の増加に起因しています。さらに、製品のFDA承認数の増加もLVADの採用増加に寄与しています。2019年10月、医療技術のパイオニアであるMedtronic plcは、現在開発中の進行性心不全患者向けMedtronic Fully Implantable LVADについて、米国食品医薬品局(FDA)から画期的装置の指定を受けた。
世界の心臓ポンプ市場は、北米(米国、カナダ)、欧州(英国、イタリア、スペイン、ドイツ、フランス、その他の欧州地域)、アジア太平洋(インド、中国、日本、韓国、その他アジア地域)、世界のその他の中東・アフリカ(中東およびアフリカ、ラテンアメリカ)を含む地域別にさらに細分化されています。なかでもアジア太平洋は、心不全の有病率の増加や、新興国における可処分所得の増加に伴うライフスタイルの変化がアジア太平洋の心臓ポンプ装置市場を牽引していることから、世界全体で大きなシェアを占めると予想されます。
すべての地域の中で、北米地域は予測期間中にかなりのCAGRで成長すると予測されています。北米市場を牽引する主な要因としては、心血管疾患(CVDs)や心不全による心臓移植の需要増が挙げられます。Heart Disease and Stroke Statistics 2022によると、2019年、米国ではCVDが根本的な死因として挙げられ、87万4,613人の死亡を占めました。2019年、米国では約40秒に1人が心筋梗塞を発症し、平均3分30秒に1人が脳卒中で死亡しています。しかし、既存の需要を満たすのに十分な移植用心臓が入手できないため、不足の危機が生じた。さらに、米国保健資源サービス局(HRSA)によると、2023年9月現在、心臓移植待機者は3,292人です。したがって、心臓ポンプ装置は今後数年間で、膨大な利用率と需要が見込まれます。
Title: Global Heart Pump Device Market Size, Share & Trends Analysis Report by Type (Implanted Heart Pump Devices and Extracorporeal Heart Pump Devices), by Product (Ventricular Assist Devices, Total Artificial Hearts (TAHs), and Extracorporeal Membrane Oxygenation (ECMO)), and by End-User (Hospital and Cardiac Centers)Forecast Period (2023-2030).
The global heart pump device market is anticipated to grow at a CAGR of 21.4% during the Forecast Period (2023-2030). Pivotal factors including the increasing number of individuals suffering from cardiovascular diseases (CVD), rising incidences of heart failure are driving the market growth. According to the World Health Organization, Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. Further, the increasing investment in R&D for heart pump products is projected to drive market growth by promoting increased acceptance and usage of these devices. In October 2022, BiVACOR®, a preclinical medical device company developing a Total Artificial Heart, received a $750k grant from the Australian Government through its medical research future fund (MRFF) and targeted translation research accelerator (TTRA) program.
The global heart pump device market is segmented on the type, and end user. Based on the type, the market is sub-segmented into implanted heart pump devices and extracorporeal heart pump devices. Based on the product, the market is sub-segmented into ventricular assist devices, intra-aortic balloon pumps (IABPs) and extracorporeal membrane oxygenation (ECMO). Further, on the basis of end user, the market is sub-segmented into hospital and cardiac centers. Among the end user, the hospitals sub-segment is anticipated to hold a considerable share of the market, owing to the well-equipped settings, easily accessible, trust and reliability.
Among the product, the ventricular assist devices sub-segment is expected to hold a considerable share of the global heart pump device market. The segmental growth is attributed to the rising incidences of temporary heart failure, temporarily used of LVAD while waiting for a donor heart to become available, increasing use of LVAD who can't have a heart transplant because of age or other factors. Additionally, the rising number of FDA approvals of the products are also contributing to the increasing adoption for LVAD. In October 2019, Medtronic plc, the pioneer in medical technology, received breakthrough device designation from the US Food and Drug Administration (FDA) for the Medtronic Fully Implantable LVAD for patients with advanced heart failure, currently in development.
The global heart pump device market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, Asia pacific is anticipated to hold a prominent share of the market across the globe, owing to the increasing prevalence of heart failure, and the and changes in lifestyles owing to rising disposable income in emerging economies are driving the heart pump device market in the Asia Pacific.
Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. The major factors driving the North America market includes the increasing demand for heart transplantation owing to the Cardiovascular diseases' (CVDs) and heart failure. According to the Heart Disease and Stroke Statistics 2022, in 2019, CVD listed as the underlying cause of death, accounted for 874,613 mortalities in the US. In 2019, approximately every 40 seconds, one person in the US suffered with a myocardial infarction and on average people died of stroke every 3 minutes 30 seconds in the country. Though, the unavailability of adequate hearts for transplantation to meet the existing demand resulted in shortage crisis. Furtermore, according to the Health Resources and Services Administration (HRSA) US, as of September 2023, there were 3,292 candidates on heart transplant waiting list. Thus, the heart pump device is expected to witness a huge utilization and demand in the coming years.
The major companies serving the global heart pump device market include: Abbott Laboratories, Berlin Heart GmbH, Boston Scientific Corp., Medtronic plc, Terumo Corp., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2022, Johnson & Johnson Inc. and Abiomed, a global provider in breakthrough heart, lung, and kidney support technologies, entered into a definitive agreement under which Johnson & Johnson acquired through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380.0 per share in cash, corresponding to an enterprise value of approximately $16.6 billion which includes cash acquired. The acquisition added heart recovery solutions to complement its Biosense Webster electrophysiology business, allowing the company expand in high-growth markets.